Helicobacter pylori infection historical perspective
|
Helicobacter pylori infection Microchapters |
|
Differentiating Helicobacter pylori infection from other Diseases |
|---|
|
Diagnosis |
|
Guideline Recommendation |
|
Treatment |
|
Case Studies |
|
Helicobacter pylori infection historical perspective On the Web |
|
American Roentgen Ray Society Images of Helicobacter pylori infection historical perspective |
|
Helicobacter pylori infection historical perspective in the news |
|
Blogs on Helicobacter pylori infection historical perspective |
|
Directions to Hospitals Treating Helicobacter pylori infection |
|
Risk calculators and risk factors for Helicobacter pylori infection historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yamuna Kondapally, M.B.B.S[2]
Overview
The association between helicobacter pylori and peptic ulcers was made by Barry Marshall and Ribin Warren in the year 1984 for which they were awarded the Nobel Prize in 2005 in physiology or medicine.
Historical Perspective
- The association between Helicobacter pylori and peptic ulcers was made by Barry Marshall and Robin Warren in the year 1984.[1][2][3][4]
- In 1994, the national institute of health (NIH) consensus development panel concluded that there is a strong association between H. pylori and ulcer disease, and recommends that ulcer patients with H. pylori infection be treated with antibiotics.[5]
- In 1994, the International Agency for Research on Cancer (IARC) concluded that H.pylori is a group I human carcinogen for gastric adenocarcinoma.[6]
- In 1997, the United States FDA approved three H.pylori regimens for the eradication of H. pylori infection. They are[7]
- Regimen 1: Omeprazole+ clarithromycin
- Regimen 2: Ranitinine-Bismuth-Citrate + Clarithromycin
- Regimen 3: Bismuth subsalicylate + metronidazole + Tetracycline + an H2 receptor antagonist
- In 2002, The Maastricht 2 Consensus Report states that a 'test-to-treat' approach is recommended in adult patients under the age of 45 years.[8]
- In 2005, Barry Marshall and Robin Warren won Nobel prize in physiology or medicine for their "discovery of bacterium Helicobacter pylori and and its role in gastritis and peptic ulcer disease".[4]
References
- ↑ Fock KM, Graham DY, Malfertheiner P (2013). "Helicobacter pylori research: historical insights and future directions". Nat Rev Gastroenterol Hepatol. 10 (8): 495–500. doi:10.1038/nrgastro.2013.96. PMC 3973742. PMID 23752823.
- ↑ Kusters JG, van Vliet AH, Kuipers EJ (2006). "Pathogenesis of Helicobacter pylori infection". Clin Microbiol Rev. 19 (3): 449–90. doi:10.1128/CMR.00054-05. PMC 1539101. PMID 16847081.
- ↑ "Unidentified curved bacilli on gastric epithelium in active chronic gastritis". Lancet. 1 (8336): 1273–5. 1983. PMID 6134060.
- ↑ 4.0 4.1 Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ (1985). "Attempt to fulfil Koch's postulates for pyloric Campylobacter". Med J Aust. 142 (8): 436–9. PMID 3982345.
- ↑ "NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease". JAMA. 272 (1): 65–9. 1994. PMID 8007082.
- ↑ Tanida N, Sakagami T, Sawada Y, Shimoyama T (1997). "[Critical review on the WHO/IARC report regarding carcinogenicity of Helicobacter pylori]". Nippon Rinsho (in Japanese). 55 (4): 995–1002. PMID 9103907.
- ↑ Hopkins RJ (1997). "Current FDA-approved treatments for Helicobacter pylori and the FDA approval process". Gastroenterology. 113 (6 Suppl): S126–30. PMID 9394774.
- ↑ Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G (2002). "Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report". Aliment. Pharmacol. Ther. 16 (2): 167–80. PMID 11860399.